key: cord-0889126-mpe7r2a8 authors: Kopanczyk, Rafal; Kumar, Nicolas; Papadimos, Thomas title: Post-Acute COVID-19 Syndrome for Anesthesiologists: A Narrative Review and a Pragmatic Approach to Clinical Care date: 2021-10-03 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2021.09.051 sha: 7680cac0c4c04741c7a0de8538c1bc81c1cc8bde doc_id: 889126 cord_uid: mpe7r2a8 Post-acute coronavirus disease 2019 (COVID-19) syndrome is a novel, poorly understood clinical entity with life-impacting ramifications. Patients with this syndrome, also known as “COVID-19 long-haulers,” often present with non-specific ailments involving more than one body system. The most common complaints include dyspnea, fatigue, brain fog, and chest pain. There is currently no single agreed-upon definition for post-acute COVID-19 syndrome, but most agree that criterion for this syndrome is the persistence of mental and physical health consequences after initial infection. Given the millions of acute infections in the U.S. over the course of the pandemic, perioperative providers will encounter these patients in clinical practice in growing numbers. Symptoms of the COVID-19 long-haulers should not be minimized as these patients are at higher risk for postoperative respiratory complications and perioperative mortality for up to 7 weeks after initial illness. Instead, a cautious multidisciplinary preoperative evaluation should be performed. Perioperative care should be viewed through the prism of best practices already in use such as avoidance of benzodiazepines in patients with cognitive impairment and use of lung protective ventilation. Recommendations especially relevant to the COVID-19 long-haulers include assessment of critical care myopathies and neuropathies to determine suitable neuromuscular blocking agents and reversal, preoperative workup of insidious cardiac or pulmonary pathologies in previously healthy patients, and thorough medication review, particularly of anticoagulation regimens and chronic steroid use. In this article, we define the syndrome, synthesize the available scientific evidence, and make pragmatic suggestions regarding the perioperative clinical care of COVID-19 long-haulers. As the rate of new respiratory syndrome coronavirus 2 (SARS-CoV-2) infections continues to increase with the dominance of the delta variant, there is a growing number of reports describing a post-acute coronavirus disease 2019 (COVID- 19) syndrome. 1 Patients with this syndrome, colloquially known as -COVID-19 long-haulers,‖ present with a constellation of non-specific symptoms of mild to life-threatening consequences. 2 Given the millions of acute infections with SARS-CoV-2 around the globe, clinicians will encounter COVID-19 longhaulers in practice in the aftermath of the pandemic. There are no current recommendations that would aid anesthesiologists when caring for these patients because of the novelty and our current fragmentary understanding of post-acute COVID-19 syndrome (PACS). Thus, we gathered available data on PACS and applied it to the perioperative setting in order to define the syndrome, describe the available scientific evidence, and make pragmatic recommendations regarding approaches to clinical care of the COVID-19 long-haulers. After the removal of duplicate citations, our literature search yielded a total of 2,414 unique citations. Of the potentially eligible abstracts identified, 2,327 did not satisfy the inclusion criteria based on title and abstract alone. The remaining 87 abstracts had their full-text citations retrieved for review. 5 additional citations were identified after hand-searching the reference list of the included studies; therefore, our review ultimately encompasses the findings of 92 full-text citations. Specifically, these includes 60 prospective studies, 18 case reports, [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] 12 retrospective studies, [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] and 2 bidirectional studies. 93, 94 There were no randomized controlled trials identified. A full flow diagram for study inclusion can be seen in Figure 1 . 40 publications reported on PACS prevalence, symptomatology, risk factors, and outcomes. 3-21, 23-26, 28-35, 63, 81-86, 93, 94 The remaining 52 articles addressed organ-specific sequelae of PACS, including 17 neuropsychiatric studies, 36-44, 64-69, 92 16 cardiovascular studies, 45-54, 70-74, 87 10 pulmonary studies, 55-60, 75-77, 88 3 hematological studies, 62, 80, 91 3 gastrointestinal studies, 78, 79, 89 and 3 endocrine studies. 27, 61, 90 The populations studied were heterogenous, including patients who did not require hospitalization, those hospitalized for more severe illness, and those who required admission to the intensive care unit (ICU). Additionally, most studies evaluated patients 1-6 months after acute disease, with only 2 articles 19, 25 having study periods of 12 months. Although there are no established criteria for PACS, most publications agree on a basic premise: the persistence of mental and physical health consequences after initial infection. 95 However, the exact temporal course of long COVID is currently undetermined, and no single definition is universally employed. According to the Centers for Disease Control (CDC), the criteria for PACS is met if symptoms persist for > 4 weeks. 1 Meanwhile, the National Institute for Health and Care Excellence (NICE) requires a 12-week period to make the diagnosis. 96 At this time, studies that directly investigate the temporal course of PACS are missing. Moreover, while very sensitive, these definitions encompass a heterogenous patient population of those recovered from asymptomatic or mild infection in addition to those who were severely ill. 1 Notably, long-term consequences of a critical illness, also known as post-intensive care syndrome (PICS), are now being considered as part of PACS. 97 Given this ambiguity, subgroup analyses concentrating on severity of illness are needed, and as more data emerges, definitions are likely to evolve. For example, expanding PACS to include the subcategory of PICS for patients who required intensive care would add clarity to current terminology. Nevertheless, for the purpose of this article, broad definition of PACS established by the CDC will be utilized, with a goal of making pragmatic suggestions regarding the perioperative clinical care of all patients with chronic sequelae of COVID-19. The reported prevalence of PACS among the collected reports ranged from roughly 20% 61 to 95%. 10 Fatigue and dyspnea were the most common symptoms, usually occurring in more than half of the studied population. 3-21, 23-26, 28-35, 63, 81-86, 94, 98 Other frequently reported complaints included smell and taste disturbances, cough, myalgias and arthralgias, sleep disturbances, anxiety, depression, post-traumatic stress disorder (PTSD), and cognitive impairment. 2 Lastly, limited amount of individuals reported palpitations, hair loss, and diarrhea, and rashes. 2 We found 4 studies that evaluated long-term mortality. 19, 31, 85, 86 An analysis of the US Veterans Affairs' (VA) data estimated mortality at 6 months to be about 8 per 1,000 nonhospitalized persons and 29 per 1,000 hospitalized persons. 85 Meanwhile, data from the UK's National Health Service (NHS) found a significantly higher mortality rate among previously hospitalized patients -12.3% at an average follow-up period of 140 days. 86 This NHS data also showed a readmission rate of 29.4%, which is comparable to the 19.9% readmission rate at 60 days reported by a separate VA study. 31 Additional studies validating these findings are needed to more accurately risk stratify these patients. Several reports revealed potential risk factors for developing chronic disease. 7, 99 Severity of acute illness is most strongly associated with long-term sequelae; thus, ICU survivors have the highest risk. 6 Other factors that were associated with long-term sequalae included higher body mass index, pre-existing respiratory disease, older age, female sex, and Black/Asian/minority ethnicities. 33 Abnormal radiologic findings, reduced quality of life scores, and decreased pulmonary function on spirometry found on follow-up examination after acute disease also corresponded to an increase risk of developing PACS. 16 Anesthesiologists should be vigilant when caring for patients with these risk factors and consider further preoperative workup when encountering patients with symptoms consistent with PACS. Current reports suggest that COVID-19 long-haulers experience sequelae in multiple body systems, though the mechanisms of organ-specific dysfunction are unclear. Possible causes include virus-specific tissue damage, 100 dysregulated immune and inflammatory response to the initial insult, 101 and PICS. 102 Although not fully elucidated, these have significant consequences on anesthetic care. Given the novelty and scientific uncertainty, the overall approach to perioperative management should be pragmatic, with strict adherence to previously established standards of care. Preoperatively, symptoms should not be minimized but addressed in a multidisciplinary fashion. Deferring evaluation to the day of surgery should be strongly discouraged, except for urgent or emergent situations. As such, institutions need to develop preoperative evaluation and risk assessment protocols for patients who previously had COVID-19. 103 Until more specific scientific evidence emerges, care of COVID-19 long-haulers should be viewed through the prism of best practices already in use. Such practices will be discussed below, categorizing them by organ systems. A summary of symptoms can be viewed in Figure 2 , and this review's key recommendations in Figure 3 . Several neuropsychiatric sequelae of PACS that are relevant to anesthesiologists have been described in the emerging literature. These include cognitive dysfunction, anxiety, depression, PTSD, chronic pain, and complications of acute structural lesions. Dysfunction in reasoning, spatial planning, problem solving, and verbal fluency have been found to be the basis of what is commonly referred to as -brain fog.‖ 104 Numerous reports of residual cognitive dysfunction have been published, estimating significant cognitive deficits in about 1/3 of recovered individuals who did not require hospitalization and in as high as 2/3 of recovered individuals who required hospitalization for acute infection. [39] [40] [41] [42] 64 Although severity of initial disease was found to be a risk factor for cognitive problems, even patients with mild disease were more likely to develop cognitive deficits compared to matched controls. 39 Among other psychiatric sequalae of PACS, anxiety and depression were reported to occur in 12-47% of patients, with higher rates in individuals requiring hospitalization. 36 Symptoms consistent with PTSD have been also been reported in roughly 10% of recovered patients, regardless whether they were hospitalized or not. 37, 38 Additionally, recent articles also commented on chronic pain experienced by COVID-19 long-haulers. 6, 20, 44, 92 Myalgias, arthralgias, and headaches are among the most common complaints, and 1 study 44 noted the associated use of pain medications (including non-opioids) and quality of life implications of moderate-to-severe pain. Finally, many severely ill individuals suffered structural damage from ischemic or hemorrhagic strokes, anoxic brain injury, or seizures. [105] [106] [107] Other serious neurologic sequalae stemmed from immunemediated reactions such as acute disseminated myelitis, encephalitis, vestibular neuritis, and late presenting Guillain-Barre Syndrome (GBS). 67-69 A follow-up study of patients developing neurologic manifestations during acute infection found that about 9 in 10 patients reported persisting deficits at 6 months, reflecting the pervasive and significant neurologic disability encountered in clinical practice. 39 Neuropsychiatric sequelae of post-acute COVID-19 syndrome have important implications on perioperative care. First, initial evaluation should consist of focused history and physical exam; noting baseline deficits, palsies, and asymmetries is especially important. 108, 109 Patients with anxiety/depression should have their therapies continued and offered premedication preoperatively. 110 However, due to an increased risk of postoperative delirium and cognitive dysfunction, benzodiazepine use is generally discouraged in individuals older than 65 and in patients experiencing cognitive dysfunction. 111 Additionally, although low doses of ketamine are now being used as a therapy for PTSD, long-haulers with PTSD may not benefit from its use for sedation due to the risk of traumatic hallucinations with anesthetic doses. 112 Moreover, the functionality of cerebral autoregulation is unknown, especially in individuals with anoxic brain injury, strokes, or dysautonomia, making cerebral perfusion pressure potentially more dependent on adequate blood pressure. 113 Until more data is available, maintaining mean arterial pressure close to baseline is encouraged. Furthermore, neuromuscular blocking strategies should take under consideration risk factors for hyperkalemic response in individuals with history of strokes, immobility, and denervated muscles. 114 Patients with critical illness neuropathy may especially benefit from quantitative monitoring of neuromuscular blockade depth, like acceleromyography, and reversal with sugammadex. 115 Finally, for patients experiencing chronic pain, multimodal analgesia is paramount, with specific concentration on neuropathic modalities in individuals suffering from critical illness neuropathy (CIN). 116 Risk of opioid dependence in COVID-19 long-haulers has not yet been evaluated; however, individuals suffering from PICS have been shown to be at increased risk and should be planned for accordingly. 117 For this reason, these patients maybe good candidates for regional or neuraxial anesthesia; nevertheless, individuals suffering from acquired peripheral or inflammatory neuropathies such as CIN or GBS require particular caution and discussion with their anesthesiologist. The limited safety data on regional or neuraxial techniques in patients with neuropathies is currently equivocal. As such, the American Society of Regional Anesthesia recommends careful discussion of risks and benefits on a case-by-case basis. 118 Anesthesiologists should especially be aware of the substantial cardiovascular disease experienced by COVID-19 survivors. Chest pain and palpitations are the most common subjective findings. 2 Objectively, individuals recovering from acute infection have been found to be at risk for lasting vascular, 45, 70 pericardial, 71 and myocardial inflammation. 46 In studies of COVID-19 survivors evaluated with cardiac magnetic resonance (CMR), ongoing cardiac inflammation was present in anywhere from 0-60% of participants. [46] [47] [48] [49] These findings suggest that long term sequelae such as arrhythmias and heart failure are possible even in seemingly healthy patients. This was recently substantiated by evaluations of resting heart rates after acute illness. 50, 51 In 1 of these studies, COVID-19 positive individuals experienced prolonged relative tachycardia that lasted on average 79 days after symptom onset; 13.7% of patients did not return to resting heart rate baseline until after 133 days. 50 Previously hospitalized appear to be at risk for even more severe sequalae. For example, a 140-day follow-up study in UK found the risk of heart failure, arrhythmias, myocardial infarction, and stroke to be 3 times that of matched controls. 72 Other complications have been reported as well. For instance, development of postural orthostatic tachycardia syndrome (POTS) and orthostatic intolerance without hemodynamic effects have been described in literature. 73, 74, 87 Finally, right ventricular dysfunction in response to fibrotic lung damage, pulmonary hypertension, and/or clot burden in people recovering from severe disease has now also been reported. [52] [53] [54] These studies consistently demonstrated an incidence of diastolic dysfunction of roughly 32-55% and an incidence of pulmonary hypertension of roughly 10%-35% after up to 12 weeks following acute disease. [52] [53] [54] Given the significance of cardiac burden from COVID-19, cardiovascular challenges should also be anticipated perioperatively. The most common symptoms of chest pain and palpitations could have a significant underlying cause. Given that myocardial damage such as inflammation and fibrosis have been found in these patients, palpitations can be a potential symptom of conduction abnormalities or ventricular dysfunction. 119 Chest pain, although likely atypical in nature and related to respiratory sequelae, should not be minimized and investigated with focused history and physical examination for heart failure, coronary artery disease, and arrhythmias; obtaining an electrocardiogram, thyroid stimulating hormone (TSH) level, and transthoracic echocardiogram may be prudent, especially when other worrisome symptoms are present. 120 Intraoperatively, patients with significant cardiac abnormalities require invasive monitoring and preparation of vasopressors, inotropes, and antiarrhythmic medications, depending on underlying pathology. 121 A constellation of palpitations, chest pain, fatigue, and postural dizziness may be indicative of POTS. 122 Patients with these symptoms should be further evaluated, preferably with tilt-table test, or by a specialist in an autonomic specialty clinic. Due to adrenergic receptor hypersensitivity, patients with POTS can exhibit labile hemodynamics intraoperatively due to overcorrections of blood pressure (BP) and heart rate in response to reductions in BP. Volume administration and careful titration of phenylephrine have been suggested as therapies of choice for hypotension. 123 Lastly, right ventricular dysfunction should be of particular concern in individuals who suffered from severe disease and continue to have respiratory dysfunction with other symptoms associated with heart failure. 124 Echocardiographic evaluation is prudent, and intraoperative availability of invasive monitoring and inotropic support is paramount. 125 Pulmonary Respiratory sequelae are the second most common ailments reported by COVID longhaulers, with shortness of breath (SOB) and cough being the most frequent. Numerically, SOB has been noted in 8-98% of patients, and cough 10-75%, with lower prevalence in patients with mild initial disease. 2 Patients with severe dyspnea tended to exhibit abnormal performance on 6-minute walk tests. 55 These complaints and functional limitations have their basis in underlying lung pathology. 56 Radiographically, multiple reports note abnormal chest x-rays and computed tomography (CT) scans on 3-6-month follow-ups, with ground-glass opacities and architectural distortion being the most common. 54, 57, 75, 76 These findings on CT scan are also correlated with abnormal pulmonary function test results. Functional evaluation of lung disease commonly revealed reduced diffusion capacity for carbon monoxide (DLCO), with a range between 21-50% of patients. 57, 58, 88 Moreover, female sex and an ICU admission were found to be risk factors for DLCO <60% of predicted at 4 months. 58 Other notable spirometry findings included mixedrestrictive flow patterns and impaired alveolar volume on spirometry. 55, 88 A study evaluating the incidence of interstitial lung disease (ILD) after hospitalization found that 4.8% of patients developed ILD, 59 with an organizing pneumonia-like pattern similar to that seen in patients of another case series. 77 Additionally, patients who required hospitalization for acute COVID-19 also experienced ongoing oxygen requirements, tracheostomy dependence, respiratory muscle weakness, fibrotic changes, and transplantation necessity. 58 Unlike the cardiac toll of COVID-19, the severity of acute disease appears to be the main risk factor for development of these pulmonary complications. 60 The pulmonary sequelae of COVID-19 should be addressed perioperatively. Although COVID-19 survivors are at increased risk of developing postoperative respiratory failure, this risk decreases substantially ≥ 7 weeks after recovery from acute infection. 126 Nevertheless, multidisciplinary preoperative optimization is of particular importance as some patients will require a complete work-up, including a computed tomography (CT) scan of the chest, pulmonary function testing, or echocardiography. 127 On the day of surgery, patients previously hospitalized may be using inhaled bronchodilators and corticosteroids, both of which should be continued. 128 Intraoperatively, airway manipulation may be challenging in individuals previously tracheostomized, or intubated for extended periods. 129 Vocal cord injuries, subglottic stenosis, and tracheomalacia have all been described. [130] [131] [132] [133] Depending on the severity of respiratory/airway sequelae and type of surgery, use of supraglottic airway devices should be considered and offered to individuals on case-by-cases basis. Furthermore, given reports of significant fibrosis and bullae, lung protective ventilation is strongly encouraged with tidal volumes 4-8 cc/kg of predicted body weight, and driving pressures <15 cm H 2 O. 134, 135 Additionally, judicious use of intravenous fluids should be a priority to limit expansion of extravascular lung water. 136, 137 . Finally, given reports of diminished respiratory muscle strength, again, reversal of neuromuscular blockade with sugammadex should be considered. 138 Intensivists quickly recognized thromboembolic disease as a frequent complication of acute COVID-19 disease. Microthrombosis, venous clots, and arterial thrombi have all been frequently reported. 139 The pulmonary vasculature appears to especially prone to microthrombi, and while pulmonary embolism (PE) has been reported, the rate of PE varies widely in the literature. 140 A meta-analysis of 102 studies stated a prevalence of VTE and PE as roughly 15% and 8%, respectively, with higher rates in the critically ill population during acute infection. 141 Long-term effects have also been described in a case series of 4 previously healthy, young individuals who developed arterial thromboses. 80 However, the incidence of hematologic complications appears to decrease with time after recovery. For example, at 30 days, the cumulative incidence of overall thrombosis and bleeding is only 2.5% and 3.7%, respectively. 91 Likewise, an analysis of 146 previously hospitalized patients in Belgium, many of whom were on thromboprophylaxis, only revealed a single incidence of symptomatic DVT and PE at 6 weeks, and none at 6 months. 62 Many of those who survived severe disease they may be on oral anticoagulation therapy when they present for elective surgery and this will require perioperative planning. 142 Cessation of therapy should be addressed preoperatively to consider the risks and benefits; however, held medications should be promptly restarted postoperatively. 143 For acute warfarin reversal, prothrombin complex concentrates can be considered if intravascular volume is of concern; 144 rivaroxaban and apixaban can now be acutely reversed with andexanet alpha; 145 and dabigatran can be reversed with idarucizumab. 146 For patients not on anticoagulation therapy, a preoperative D-dimer measurement and/or venous ultrasound for thrombosis should be considered. 103 A Ddimer only has clinical utility if there is low suspicion for inflammation or malignancy, so prudent patient selection is necessary. 147 If a deep-vein thrombosis is identified on ultrasound, anticoagulants such as heparin can be administered in addition to prophylactic compression stockings. 147 As an additional consideration, ICU survivors may have thrombosed or injured arteries that were previously cannulated for monitoring, therefore intraoperative ultrasonographic examination before new instrumentation is advised. 148 There is currently a scarcity of literature regarding the long-term consequences of PACS on kidney function; however, some inferences can be drawn from data following early recovery from COVID-19. Acute kidney disease was prevalent in hospitalized patients with acute COVID-19 infection, with 35% not recovering to their baseline renal function upon discharge. 149 Moreover, 1 study found a greater rate of decline in glomerular filtration rate per year among recovered COVID-19 patients compared to a non-COVID-19 cohort. 150 Electrolyte imbalances, volume status issues, dialysis line infections and thrombosis, can all be encountered and require attention. 2 Intraoperatively, mean arterial pressure should target values ≥ 65 mmHg to ensure adequate renal perfusion. 151 Gastrointestinal From a gastrointestinal standpoint, 5-10% of patients developed diarrhea after resolution of acute disease. 5, 93 However, newer data suggests that gastrointestinal sequalae may be more serious in some patients. For example, 2 case reports describe 4 patients developing cholangiopathies in the months following acute disease infection, necessitating liver transplantation in 1 of these patients. 78, 79 Even among the noncritically ill, malnutrition in hospitalized patients is also a serious concern. For example, a report from Italy described nearly 50% of patients in a rehabilitation unit as malnourished after acute disease and 90% as having some degree of dysphagia. 89 As such, patients recovering from severe acute disease who present for surgery may be malnourished, dysphagic, or in need of alternate mode of nutrition delivery such as gastric, or nasoduodenal tubes. 152 Care should be taken to continue feeding as close to surgery as possible, especially when post-pyloric tubes are present. 153 Endocrine COVID-19's effect on endocrine systems has not been thoroughly investigated; however, case reports of new onset Hashimoto's, 154 Graves' disease, 155 and diabetes mellitus 156 are emerging. A follow-up study of hospitalized patients noted that a rate of new diabetes diagnosis of 29 per 1000 on average 140 day. 90 Additionally, 2 studies evaluated long-term thyroid function after acute disease. 27, 61 Most patients who had abnormal thyroid function during acute hospitalization had normalized function on follow-up; however, 3-5% developed anti-thyroid peroxidase antibodies, and <2 % developed subclinical thyrotoxicosis, and hypothyroidism. 61 It is also crucial to consider the iatrogenic effects of dexamethasone therapy on the hypothalamicpituitary-adrenal axis. 157 During the preoperative endocrinology workup, patients with symptoms worrisome for arrhythmias should have their thyroid function evaluated. 158 Also, recent steroid therapy should be investigated, and perioperative stress doses administered in patients at risk for functional adrenal insufficiency. 159 Although the data is limited on when it is safe to schedule an elective surgery after acute infection, it has been suggested that patients recovering from COVID-19 are at increased risk of a 30-day adjusted mortality when undergoing elective or emergent surgery. 126 The latest international, multicenter, prospective cohort study found that risk of mortality returned to baseline ≥ 7 weeks after recovery from COVID-19 infection; however, patients with persisting symptoms continued to have increased mortality even after 7 weeks. 126 Patients at highest risk were those undergoing emergency surgery and those with an American Society of Anesthesiologists (ASA) physical status of III-V presenting for surgery within 6 weeks of initial illness. In concert with these findings, the ASA and the Anesthesia Patient Safety Foundation (APSF) recommend at least a 12-week delay before undergoing elective surgery for patients who experienced a critical illness, 10 weeks for diabetic/hospitalized/immunocompromised patients, 6 weeks for symptomatic patients not requiring hospitalization, and 4 weeks for asymptomatic individuals or those with mild, non-respiratory symptoms. 160 Nevertheless, the decision of when to proceed with a surgery must be reached by discussing the increased perioperative hazards with the potential health risks of delaying the procedure. Currently, no data exists regarding differences in outcomes between monitored anesthesia care (MAC) versus general or neuraxial anesthesia in the COVID-19 long-hauler population. Therefore, until further analysis emerges, practitioners should exercise clinical prudence when devising an anesthetic plan for these patients. Studies on post-acute COVID-19 syndrome are just beginning to materialize. With time, bedside practitioners will possess more data in their armamentarium to make evidence-based decisions. Currently, it is of paramount importance to approach COVID-19 long-haulers in a multidisciplinary fashion. Symptoms should not be minimized as life-threating entities like pulmonary artery hypertension, severe lung fibrosis, and ventricular failure may be present. In the perioperative setting, practitioners should exemplify a pragmatic approach, and use best practices from similar disease states to guide perioperative care. None of the authors have any conflicts of interest to report. No funding from the NIH, HHMI, or any other financial source was received for conducting this study. Rafal Kopanczyk: This author helped to conduct the literature search, analyze the data, and write the manuscript. Nicolas Kumar: This author helped to conduct the literature search and write the manuscript. Thomas Papadimos: This author helped analyze the data and write the manuscript. Information for Healthcare Providers Post-acute COVID-19 syndrome ‗Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19 Long COVID in the Faroe Islands-a longitudinal study among non-hospitalized patients Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients Attributes and predictors of long COVID Long-COVID Syndrome? A study on the persistence of neurological, psychological and physiological symptoms. in Healthcare Clinical predictors of long COVID-19 and phenotypes of mild COVID-19 at a tertiary care centre in India Recovery from COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group members Long-coronavirus disease among people living with HIV in western India: An observational study. Immunity, Inflammation and Disease Patients with uncomplicated COVID-19 have longterm persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic Persistent post-covid symptoms in healthcare workers Reluctant pioneer': A qualitative study of doctors' experiences as patients with long COVID Post COVID-19 Syndrome (Long Haul Syndrome): Description of a Multidisciplinary Clinic at the Mayo Clinic and Characteristics of the Initial Patient Cohort The COVID-19 sequelae: a cross-sectional evaluation of postrecovery symptoms and the need for rehabilitation of COVID-19 survivors Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet Regional Health Post-covid Syndrome: A Single-Center Questionnaire Study On 1007 Participants Recovered from COVID-19 Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study Follow-up of COVID-19 recovered patients with mild disease Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. The Lancet Infectious Diseases Post-Acute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort Persistence of COVID-19 symptoms after recovery in Mexican population Sequelae in adults at 12 months after mild-tomoderate coronavirus disease 2019 (COVID-19) Refining -Long-COVID‖ by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection Insights From Prospective Follow-up of Thyroid Function and Autoimmunity Among Covid-19 Survivors Day by day symptoms following positive and negative PCR tests for SARS-CoV-2 in non-hospitalised health-care workers: a 90-day follow-up study Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-based Cohort Study Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study Readmission and death after initial hospital discharge among patients with COVID-19 in a large multihospital system Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation Persistent Symptoms in Patients Recovering From COVID-19 in Denmark Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study The high mental health burden of -Long COVID‖ and its association with on-going physical and respiratory symptoms in all adults discharged from hospital Post-traumatic stress disorder among COVID-19 survivors at 3-month follow-up after hospital discharge Prevalence and risk factors for post-traumatic stress in hospitalized and non-hospitalized COVID-19 patients A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 -long haulers‖ Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables Post-infection cognitive impairments in a cohort of elderly patients with COVID-19 Persisting olfactory dysfunction improves in patients 6 months after COVID-19 disease Myalgia as a symptom at hospital admission by severe acute respiratory syndrome coronavirus 2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18 F] FDG-PET/CT study Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection Evaluation for Myocarditis in Competitive Student Athletes Recovering From Coronavirus Disease 2019 With Cardiac Magnetic Resonance Imaging Cardiac involvement in consecutive elite athletes recovered from Covid-19: A magnetic resonance study Assessment of Prolonged Physiological and Behavioral Changes Associated With COVID-19 Infection Clinical characterization of dysautonomia in long COVID-19 patients Associations between the Severity of the Post-Acute COVID-19 Syndrome and Echocardiographic Abnormalities in Previously Healthy Outpatients Following Infection with SARS-CoV-2 A Multidisciplinary Approach to Evaluate the Presence of Hepatic and Cardiac Abnormalities in Patients with Post-Acute Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea Exercise Ventilatory Inefficiency in Post-COVID-19 Syndrome: Insights from a Prospective Evaluation Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment Persistent poor health after COVID-19 is not associated with respiratory complications or initial disease severity Long COVID in Patients with Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role? Endocrine Practice Venous thromboembolism in patients discharged after COVID-19 hospitalization. in Seminars in thrombosis and hemostasis Parkinson's Disease and Post-COVID-19 Syndrome: The Parkinson's Long-COVID Spectrum Neurocognitive deficits in severe COVID-19 infection: Case series and proposed model A presumed case of new-onset focal seizures as a delayed complication of COVID-19 infection Post-COVID-19 inflammatory syndrome manifesting as refractory status epilepticus Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of ‗long COVID-19 syndrome MRI negative myelopathy post mild SARS-CoV-2 infection: vasculopathy or inflammatory myelitis Guillain-Barré syndrome after SARS-CoV-2 infection Post-COVID-19 Kawasaki-Like Syndrome Acute myopericarditis in the post COVID-19 recovery phase ST-segment elevation myocardial infarction in post-COVID-19 patients: A case series Post-COVID-19 Postural Orthostatic Tachycardia Syndrome Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience High-performance low field MRI enables visualization of persistent pulmonary damage after COVID-19 Lung Fibrosis Sequelae After Recovery from COVID-19 Infection Severe organising pneumonia following COVID-19 Post-COVID-19 Cholangiopathy: A Novel Entity Post-Covid-19 Cholangiopathy-A New Indication for Liver Transplantation: A Case Report. in Transplantation proceedings Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients Post-Discharge Symptoms among Hospitalized COVID-19 Patients in Nigeria: A Single-Center Study Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study Clinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: a retrospective cohort analysis PROMIS Scales for Assessment of Persistent Post-COVID Symptoms: A Cross Sectional Study High-dimensional characterization of post-acute sequelae of COVID-19 Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study Autonomic dysfunction following COVID-19 infection: an early experience Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection Nutritional management of COVID-19 patients in a rehabilitation unit New-onset diabetes in -long COVID‖ Postdischarge thrombosis and hemorrhage in patients with COVID-19 Three-month quality of life in survivors of ARDS due to COVID-19: A preliminary report from a French academic centre 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients Chronic COVID Syndrome: Need for an appropriate medical terminology for Long-COVID and COVID Long-Haulers COVID-19 rapid guideline: managing the long-term effects of COVID-19 Survivorship after COVID-19 ICU stay 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Risk factors associated with long-term hospitalization in patients with COVID-19: a single-centered, retrospective study Respiratory virus infections: understanding COVID-19 Is a -cytokine storm‖ relevant to COVID-19? Post intensive care syndrome prevention and impact of COVID 19 Preparing previously COVID-19-positive patients for elective surgery: a framework for preoperative evaluation Cognitive deficits in people who have recovered from COVID-19 Neurological implications of COVID-19 infections Neurological insights of COVID-19 pandemic Brain disease network analysis to elucidate the neurological manifestations of COVID-19 The clinical assessment of the patient with early dementia Neurologic Exam. StatPearls Psychiatric patient and anaesthesia Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims Cerebral blood flow autoregulation and dysautoregulation Depolarizing neuromuscular blocking drugs Neuromuscular blocking agents and neuromuscular dysfunction acquired in critical illness: a systematic review and metaanalysis Perioperative management of the chronic pain patient Post-intensive care syndrome: an overview The second ASRA practice advisory on neurologic complications associated with regional anesthesia and pain medicine: executive summary Perioperative cardiac arrhythmias Perioperative Chest Pain/Dyspnea. in Perioperative Medicine Perioperative cardiovascular monitoring of high-risk patients: a consensus of 12 Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients Postural orthostatic tachycardia syndrome and general anesthesia: a series of 13 cases Right Ventricular Dysfunction in Patients with Coronavirus Disease 2019 Supported with Extracorporeal Membrane Oxygenation Anaesthesia and right ventricular failure Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study Preoperative evaluation of pulmonary function: validity, indications, and benefits Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective Multidisciplinary safety recommendations after tracheostomy during covid-19 pandemic: state of the art review A prospective study of voice, swallow, and airway outcomes following tracheostomy for COVID-19 Vocal Cord Ulcer Following Endotracheal Intubation for Mechanical Ventilation in COVID-19 Pneumonia: A Case Report from Northern Italy Tracheostomy in the COVID-19 pandemic Post-intubation tracheal stenosis in COVID-19 patients Intraoperative protective mechanical ventilation for prevention of postoperative pulmonary complications: a comprehensive review of the role of tidal volume, positive end-expiratory pressure, and lung recruitment maneuvers Pulmonary emphysema, bullae, and pneumothorax in COVID-19 pneumonia Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery Liberal or restricted fluid administration: are we ready for a proposal of a restricted intraoperative approach? COVID-19 and acute sarcopenia Incidence of venous thromboembolism in hospitalized patients with COVID-19 Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature Reversing factor Xa inhibitors-clinical utility of andexanet alfa Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants Elective laparoscopic colectomy in a patient 3 weeks after coronavirus disease 2019 infection: a case report Ultrasonography as a guide during vascular access procedures and in the diagnosis of complications AKI in hospitalized patients with COVID-19 Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19 Blood pressure targets in perioperative care: provisional considerations based on a comprehensive literature review Postintubation dysphagia during COVID-19 outbreak-contemporary review Perioperative nutrition support: who and how COVID-19 complicated by Hashimoto's thyroiditis SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19 New-onset diabetes in Covid-19 The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone Perioperative management of thyroid dysfunction Supplemental perioperative steroids for surgical patients with adrenal insufficiency Considerations for Elective Surgery in the Post-COVID-19 Patient We would like to thank Ronald Harter, MD and Ravi Tripathi, MD for departmental support.